目的 探讨参芍胶囊联合环磷腺苷葡胺注射液治疗心肌梗死的临床疗效。方法 选取2017年1月-2017年12月周至县人民医院收治的心肌梗死患者90例为研究对象，按照随机数字表法将所有患者分为对照组和治疗组，每组各45例。对照组静脉滴注环磷腺苷葡胺注射液，180 mg/次，1次/d。治疗组在对照组治疗的基础上口服参芍胶囊，1 g/次，3次/d。两组患者均连续治疗2周。观察两组的临床疗效，同时比较两组治疗前后心功能指标和心肌损伤标志物水平。结果 治疗后，对照组和治疗组的总有效率分别为77.78%、93.33%，两组比较差异有统计学意义（P<0.05）。治疗后，两组左室射血分数（LVEF）、每搏输出量（SV）明显升高，舒张早期流速峰值/舒张晚期流速峰值（E/A值）明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组心功能指标明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组肌酸激酶同工酶（CK-MB）、心肌肌钙蛋白I（cTnI）、N末端B型利钠肽原（NT-proBNP）、心型脂肪酸结合蛋白（H-FABP）水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组心肌损伤标志物水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 参芍胶囊联合环磷腺苷葡胺注射液治疗心肌梗死具有较好的临床疗效，可减轻心肌损伤，改善心功能，具有一定临床推广应用价值。

Objective To investigate the effect of Shenshao Capsules combined with Meglumine Adenosine Cyclophosphate Injection in treatment of myocardial infarction. Methods Patients (90 cases) with myocardial infarction in Zhouzhi County People's Hospital from January 2017 to December 2017 were randomly divided into control and treatment groups, and each group had 45 cases. Patients in the control group were iv administered with Meglumine Adenosine Cyclophosphate Injection, 180 mg/time, once daily. Patients in the treatment group were po administered with Shenshao Capsules on the basis of the control group, 1 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and cardiac function indexes and the levels of myocardial injury markers in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 77.78% and 93.33%, respectively, and there was difference between two groups (P < 0.05). After treatment, LVEF and SV in two groups were significantly increased, but E/A in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the cardiac function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of CK-MB, cTnI, NT-proBNP, and H-FABP in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the levels of myocardial injury markers in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Shenshao Capsules combined with Meglumine Adenosine Cyclophosphate Injection has clinical curative effect in treatment of myocardial infarction, can alleviate myocardial injury, and improve heart function, which has a certain clinical application value.